Missed NVDA?
Don’t Miss the Next One.
Join 5,000+ investors using Ticker Nerd’s Market Radar to stay ahead of major market moves, analyst upgrades, and trending opportunities — for free.
WAT Stock Forecast 2026-2027
$327.84
Current Price
$32.18B
Market Cap
Buy 12
Hold 10
Sell 0
Wall St Analyst Ratings
Distance to WAT Price Targets
+43.4%
To High Target of $470.00
+15.1%
To Median Target of $377.50
+0.7%
To Low Target of $330.00
WAT Price Momentum
+2.5%
1 Week Change
+9.4%
1 Month Change
+2.1%
1 Year Change
-13.7%
Year-to-Date Change
-20.8%
From 52W High of $414.15
+19.2%
From 52W Low of $275.05
📊 TOP ANALYST CALLS
Did WAT Make This Month's Elite Buy List?
We don't follow just any analyst — only the top 3% with a proven track record make our cut. See if Waters is one of their latest high-conviction picks.
Latest WAT Stock Price Targets & Analyst Predictions
Based on our analysis of 30 Wall Street analysts, WAT has a bullish consensus with a median price target of $377.50 (ranging from $330.00 to $470.00). The overall analyst rating is Strong Buy (8.0/10). Currently trading at $327.84, the median forecast implies a 15.1% upside. This outlook is supported by 12 Buy, 10 Hold, and 0 Sell ratings.
Conversely, the most conservative target is provided by Lu Li at UBS, suggesting a 0.7% upside.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
WAT Analyst Ratings
12
Buy
10
Hold
0
Sell
WAT Price Target Range
Low
$330.00
Average
$377.50
High
$470.00
Current: $327.84
Latest WAT Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for WAT.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| Apr 13, 2026 | UBS | Lu Li | Neutral | Maintains | $330.00 |
| Mar 25, 2026 | Deutsche Bank | Justin Bowers | Hold | Maintains | $330.00 |
| Feb 23, 2026 | Morgan Stanley | Kallum Titchmarsh | Equal-Weight | Maintains | $350.00 |
| Feb 11, 2026 | Wells Fargo | Brandon Couillard | Equal-Weight | Maintains | $355.00 |
| Feb 11, 2026 | Barclays | Luke Sergott | Overweight | Reinstates | $400.00 |
| Feb 10, 2026 | Guggenheim | Subbu Nambi | Buy | Reiterates | $440.00 |
| Feb 10, 2026 | B of A Securities | Derik De Bruin | Neutral | Maintains | $350.00 |
| Feb 10, 2026 | UBS | Dan Leonard | Neutral | Maintains | $370.00 |
| Jan 27, 2026 | HSBC | Sidharth Sahoo | Buy | Initiates | $460.00 |
| Jan 5, 2026 | William Blair | Matt Larew | Outperform | Initiates | $N/A |
| Dec 15, 2025 | Wells Fargo | Brandon Couillard | Equal-Weight | Maintains | $415.00 |
| Dec 10, 2025 | Wolfe Research | Doug Schenkel | Outperform | Upgrade | $480.00 |
| Dec 2, 2025 | Morgan Stanley | Kallum Titchmarsh | Equal-Weight | Initiates | $423.00 |
| Nov 5, 2025 | Wells Fargo | Brandon Couillard | Equal-Weight | Maintains | $385.00 |
| Nov 5, 2025 | TD Cowen | Dan Brennan | Hold | Maintains | $390.00 |
| Oct 9, 2025 | JP Morgan | Casey Woodring | Neutral | Maintains | $325.00 |
| Oct 8, 2025 | Rothschild & Co | Natalya Davies | Buy | Initiates | $390.00 |
| Aug 5, 2025 | Wells Fargo | Brandon Couillard | Equal-Weight | Maintains | $315.00 |
| Aug 5, 2025 | Deutsche Bank | Justin Bowers | Hold | Maintains | $315.00 |
| Aug 4, 2025 | Jefferies | Tycho Peterson | Buy | Maintains | $385.00 |
Waters Corporation (WAT) Competitors
The following stocks are similar to Waters based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
Waters Corporation (WAT) Financial Data
Waters Corporation has a market capitalization of $32.18B with a P/E ratio of 30.5x. The company generates $3.17B in trailing twelve-month revenue with a 20.3% profit margin.
Revenue growth is +6.8% quarter-over-quarter, while maintaining an operating margin of +33.8% and return on equity of +29.3%.
Valuation Metrics
Market Cap
$32.18B
Enterprise Value
$33.11B
P/E Ratio
30.5x
PEG Ratio
-9.9x
Price/Sales
10.2x
Growth & Margins
Revenue Growth (YoY)
+6.8%
Gross Margin
+61.1%
Operating Margin
+33.8%
Net Margin
+20.3%
EPS Growth
-2.7%
Financial Health
Cash/Price Ratio
+1.8%
Current Ratio
1.7x
Debt/Equity
60.3x
ROE
+29.3%
ROA
+11.5%
💡 SKIP THE NOISE
97% of Analyst Ratings Go Nowhere
We filter thousands of calls to find the few that actually matter. Get the top analyst buy ratings — tracked and updated every Monday and Thursday.
Waters Corporation (WAT) Business Model
About Waters Corporation
What They Do
Provides analytical instruments and software solutions.
Business Model
Waters Corporation generates revenue by selling high-performance analytical instruments and software solutions, primarily in the fields of liquid chromatography and mass spectrometry. Its customer base includes biopharmaceutical companies, industrial manufacturers, and academic institutions, which rely on its products for research, development, quality control, and regulatory compliance.
Additional Information
The company is recognized for its gold standard instruments, particularly in biopharmaceutical research. A significant merger with BD's life science and diagnostics business in early 2026 is expected to enhance Waters' product offerings and market presence in the diagnostics sector, potentially increasing its revenue streams and customer diversity.
Company Information
Sector
Healthcare
Industry
Diagnostics & Research
Employees
7,900
CEO
Dr. Udit Batra Ph.D.
Country
United States
IPO Year
1995
Website
www.waters.comWaters Corporation (WAT) Latest News & Analysis
Latest News
Quick Summary
Waters Corporation launched the omniDAWN™ MALS Photometer, enhancing chromatographic run speeds by up to 4x, improving molar mass measurement by 10x, and reducing sample and solvent consumption significantly.
Why It Matters
The launch of the Waters omniDAWN™ MALS Photometer enhances efficiency and reduces costs in analytical processes, potentially increasing market demand and profitability for Waters Corporation.
Source: PRNewsWire
Market Sentiment:
Neutral
Quick Summary
In the quarter, new positions were established in Semtech, Tradeweb Markets, and SiTime, while investments in Edwards Lifesciences, Waters, and Arthur J. Gallagher were increased. Ares, CCC Intelligent Solutions, and Parsons were exited.
Why It Matters
The initiation of new positions and adjustments in existing holdings signal a strategic shift, potentially impacting stock performance and market sentiment in those companies.
Source: Seeking Alpha
Market Sentiment:
Neutral
Quick Summary
Waters Corporation (NYSE: WAT) shares rose after the FDA cleared its Onclarity HPV Self-Collection Kit, enhancing access to cervical cancer screening.
Why It Matters
FDA clearance for Waters Corporation's HPV Self-Collection Kit boosts market confidence and potential revenue growth, positively impacting share performance and investor sentiment.
Source: Benzinga
Market Sentiment:
Positive
Quick Summary
The FDA-approved BD Onclarity™ HPV Assay offers comprehensive HPV screening in the U.S. and includes an at-home self-collection option, targeting unscreened populations to lower cervical cancer risk.
Why It Matters
The FDA approval of the Onclarity™ HPV Assay enhances market potential for cervical cancer screening, likely boosting revenue for BD and associated partners, appealing to health-focused investors.
Source: PRNewsWire
Market Sentiment:
Neutral
Quick Summary
In the quarter, four new holdings were acquired, including Blackstone and Otis. Oracle was exited after a profitable five-year investment, and Broadcom was trimmed to invest in Taiwan Semiconductor.
Why It Matters
The shifts in holdings signal strategic reallocations, highlighting confidence in Taiwan Semiconductor and the success of Oracle's business model transition, which could influence market sentiment.
Source: Seeking Alpha
Market Sentiment:
Neutral
Waters Prices Offering of Senior Notes
1 month ago
Quick Summary
Waters Corporation has priced a $3.5 billion offering of senior notes through its subsidiary, Augusta SpinCo Corporation, with varying maturities and interest rates from 4.321% to 5.245%.
Why It Matters
Waters Corporation's $3.5 billion senior notes offering indicates strong capital raising efforts, impacting liquidity, debt levels, and potential investment returns, influencing stock valuation.
Source: PRNewsWire
Market Sentiment:
Neutral
Frequently Asked Questions About WAT Stock
What is Waters Corporation's (WAT) stock forecast for 2026?
Based on our analysis of 30 Wall Street analysts, Waters Corporation (WAT) has a median price target of $377.50. The highest price target is $470.00 and the lowest is $330.00.
Is WAT stock a good investment in 2026?
According to current analyst ratings, WAT has 12 Buy ratings, 10 Hold ratings, and 0 Sell ratings. The stock is currently trading at $327.84. Always conduct your own research and consider your investment goals before making investment decisions.
What is the long-term price prediction for WAT stock?
Wall Street analysts predict WAT stock could reach $377.50 in the next 12 months. This represents a 15.1% increase from the current price of $327.84. Please note that this is a projection by Wall Street analysts and not a guarantee.
What is Waters Corporation's business model?
Waters Corporation generates revenue by selling high-performance analytical instruments and software solutions, primarily in the fields of liquid chromatography and mass spectrometry. Its customer base includes biopharmaceutical companies, industrial manufacturers, and academic institutions, which rely on its products for research, development, quality control, and regulatory compliance.
What is the highest forecasted price for WAT Waters Corporation?
The highest price target for WAT is $470.00 from at , which represents a 43.4% increase from the current price of $327.84.
What is the lowest forecasted price for WAT Waters Corporation?
The lowest price target for WAT is $330.00 from Lu Li at UBS, which represents a 0.7% increase from the current price of $327.84.
What is the overall WAT consensus from analysts for Waters Corporation?
The overall analyst consensus for WAT is bullish. Out of 30 Wall Street analysts, 12 rate it as Buy, 10 as Hold, and 0 as Sell, with a median price target of $377.50.
How accurate are WAT stock price projections?
Stock price projections, including those for Waters Corporation, are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
Important Disclaimer
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
Last updated: April 19, 2026 3:49 PM UTC